Advertisement

Fedratinib Reduced Spleen Volume in Ruxolitinib-Resistant Myelofibrosis

Patients with myelofibrosis resistant or intolerant to ruxolitinib may have an alternative treatment option with the JAK2-selective inhibitor fedratinib, according to the results of a recent phase II study.

 Cancer Network